United BioSource Corporation (UBC; Bethesda, MD) announced the aquisition of Cognitive Drug Research (CDR), whose automative cognitive assessment system is the most popular system of its kind in the world. It's been used in more than 1000 clinical trials, encompasses 50 different disease areas, and is validated in over 60 languages. In addition, CDR maintains the industry’s largest healthy subject, drug, and patient databases of cognitive effects.
“The premier evidence base, reliability, and global reach of the CDR System coupled with UBC’s validated rater training, assessment, and rater surveillance methods will provide an unprecedented opportunity for improved signal detection in the measurement of cognition and clinically subjective endpoints,” said Ethan Leder, Chief Exectuive Officer of UBC, in a company press release. “The addition of Professor Keith Wesnes, to the UBC scientific team and our integrated offerings will provide sponsor companies with the broadest, most seamless capabilities available.”
Professor Keith Wesnes founded CDR in 1986.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.